Login  
Research Report
 
 
Home >> Country >> India >> Company
Company Name : Biocon
Y/E Mar, Rs mn FY11 FY12 FY13 FY14E FY15E
Price466
Target530
RecoBUY
Net Sales23,00320,49024,26328,51331,907
Growth (%)-11181812
EBIDTA5,8685,1735,7017,1117,648
EBITDA Margin25232524
Net Profit3,7563,1313,4834,3244,899
Growth (%)-17112413
EPS, Rs1916172224
PER, x24.829.826.821.619.0
EV/EBIDTA, x1618161312
P/BV, x54333
ROE, % 1815191415
Total debt/Equity (%)-5.3-11.7-15.11.5-1.8
Latest Reports
Date Description Country Analyst Download
09-Feb-2024 Biocon - Weak Q3; Progress on pipeline is key monitorable; Maintain Neutral with lowered TP Rs 260 India Surya Patra
15-Aug-2023 Biocon - Plants clearance remain the key to the near-term growth; Maintain BUY with TP of Rs 310 India Surya Patra
24-May-2023 Biocon Ltd- Plants and products clearance remain the key; Maintain BUY with TP Rs 330 India Surya Patra
16-Feb-2023 Biocon - Trades at a rock-bottom valuation; Maintain BUy with TP Rs 350 India Surya Patra
29-Dec-2022 Biocon - Risk-reward turned favorable; Reiterate BUY with TP of Rs 350 India Surya Patra
16-Nov-2022 Biocon (BIOS IN): Pact with Serum Inst. and Viatris to add value progress; Maintain BUY with lower TP Rs 370 India Surya Patra
01-Sep-2022 Biocon - Multiple Form-483s on biosimilar units hurts growth; Maintain BUY with lowered TP Rs 410 India Surya Patra
29-Jul-2022 Biocon - Pact with Serum Inst. and Viatris to add value progress; Maintained BUY with lower TP of Rs 440 India Surya Patra
30-Apr-2022 Biocon - Earnings to double in FY23; BUY with Target Price of Rs 500 India Surya Patra
02-Mar-2022 Biocon - Acquisition of Viatris’ biosimilar biz is value accretive; BUY with TP Rs 500 India Surya Patra
23-Feb-2022 Biocon - Superior pricing of interchangeable Glargine excites us more; BUY with TP Rs 500 India Surya Patra
24-Jan-2022 Biocon (BIOS IN): Earnings to double in FY23: Buy with raised TP of Rs 500 India Surya Patra
09-Nov-2021 Biocon - Branded interchangeable Glargine launch is incremental +ve; BUY with TP Rs 450 India Surya Patra
23-Oct-2021 Biocon - Set for a robust earnings momentum; Maintain BUY with TP Rs 450 India Surya Patra
19-Sep-2021 Biocon - Alliance with Serum Institute is a win-win deal; Maintain BUY with TP Rs 500 India Surya Patra
23-Jul-2021 Biocon (BIOS IN) - Likely traction in biosimilars soon; Maintain BUY with TP Rs 500 India Surya Patra
16-Jul-2021 Biocon - Issue of low biosimilars penetration addressed well; Upgrade to BUY with TP Rs 500 India Surya Patra
29-Apr-2021 Biocon -Hurt by underperformance in biosimilar: Downgrade to Neutral with TP Rs 450 India Surya Patra
23-Jan-2021 Biocon (BIOS IN) - Hurt by Covid-led staggered penetration of Biosimilars; Maintain BUY with TP Rs475 India Surya Patra
25-Oct-2020 Biocon - Poised for strong growth ahead; BUY with TP Rs 500 India Surya Patra
01-Sep-2020 Biocon (BIOS IN) - Semglee launch is a critical milestone; Re-initiate with Buy and TP of Rs 500 India Surya Patra
28-Feb-2020 Biocon (BIOS IN): Pegfilgrastim ramp-up will be value accretive; BUY with TP Rs 370 India Surya Patra
26-Jan-2020 Biocon(BIOS IN)-Value growth led by biologics ramp up ahead: BUY with TP Rs 370 India Surya Patra
03-Dec-2019 Biocon: Ogivri launch in the US to drive rapid value growth (BUY Maintain) India Surya Patra
25-Oct-2019 Biocon (BIOS IN) - Biologic growth outlook remains robust; Maintain BUY with TP Rs 400 India Surya Patra
1 2 3 
Copyright © 2013. Brought to you by PhillipCapital (India) Pvt. Ltd.      Designed and developed by C-MOTS Infotech (ISO 9001:2015 certified)